文献速递乳腺乳腺X线MR

对比增强乳腺X线摄影与MRI预测乳腺癌大小的准确性与精确性:究竟有多好?

Accuracy and precision of contrast enhanced mammography versus MRI for predicting breast cancer size: how "good" are they really?
PubMed 文献 · Br J Radiol · 2023-03-03

前瞻性研究纳入59例活检证实的浸润性乳腺癌患者,比较CEM与MRI预测肿瘤大小的准确性和精确性。结果显示,MRI和CESM与病理总大小的Lin一致性相关系数分别为0.75和0.71,但95%一致性界限宽泛,两种方法准确度均不足以在不经穿刺活检确认的情况下指导治疗决策。

要点

  • CEM与MRI测量乳腺癌大小均存在较大误差,不能替代活检确认指导治疗。
  • MRI与病理总大小一致率为64%,CESM为57%,两者同时一致仅46%。
  • 对浸润性成分,MRI和CESM分别有41%和50%高估。

核心结论

  • CEM和MRI均缺乏足够准确性,无法在不经穿刺活检确认的情况下指导治疗计划变更。

研究设计与样本

  • 前瞻性研究,纳入59例经穿刺活检证实的浸润性乳腺癌女性,均接受CEM和乳腺MRI检查。
  • 由两名乳腺放射科医生分别独立阅片,每人仅能访问一种检查方式。
  • CEM测量基于低能图像和重组图像,MRI测量基于第一组增强后序列。
  • 参考标准为最大浸润性恶性病灶大小(PathInvasive)和全部病灶大小(PathTotal)。
  • 预设临床一致性范围为±10 mm。

关键影像表现/征象

  • 病灶中浸润性导管癌40例(68%),其中31/40(78%)伴有导管原位癌;多灶性病变12例(20%)。
  • 中位病灶大小:浸润性成分17 mm,总大小27 mm,范围5–125 mm。

诊断标准与关键数值

  • MRI与PathTotal的Lin一致性相关系数为0.75(95% CI 0.6, 0.84),CESM为0.71(95% CI 0.56, 0.82)。
  • 对总大小,MRI平均差异为低估3%、高估4%;对浸润性成分,MRI和CESM分别高估41%和50%。
  • PathTotal的95%一致性界限从低估60%到高估2.4倍或近3倍。
  • MRI与PathTotal一致36例(64%),CESM一致32例(57%),两者均一致26例(46%)。

临床应用与阅片要点

  • 阅片时需注意CEM和MRI对浸润性成分倾向高估,报告肿瘤大小应谨慎。
  • 多灶性病变需按象限分别测量异常范围。
  • 对于治疗决策相关的大小评估,应建议活检确认而非仅依赖影像。

局限性

  • 样本量较小(59例),可能影响结果的普遍性。
  • 原文未明确报告研究是否单中心。
  • 原文未报告阅片者间一致性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate and compare the accuracy and precision of contrast-enhanced mammography (CEM) vs MRI to predict the size of biopsy-proven invasive breast cancer.

METHODS: Prospective study, 59 women with invasive breast cancer on needle biopsy underwent CEM and breast MRI. Two breast radiologists read each patient's study, with access limited to one modality. CEM lesion size was measured using low-energy and recombined images and on MRI, the first post-contrast series. Extent of abnormality per quadrant was measured for multifocal lesions. Reference standards were size of largest invasive malignant lesion, invasive (PathInvasive) and whole (PathTotal). Pre-defined clinical concordance ±10 mm.

RESULTS: Mean patient age 56 years, 42 (71%) asymptomatic. Lesions were invasive ductal carcinoma 40 (68%) with ductal carcinoma in situ (31/40) in 78%, multifocal in 12 (20%). Median lesion size was 17 mm (invasive) and 27 mm (total), range (5-125 mm). Lin's concordance correlation coefficients for PathTotal 0.75 (95% CI 0.6, 0.84) and 0.71 (95% CI 0.56, 0.82) for MRI and contrast-enhanced spectral mammography (CESM) respectively. Mean difference for total size, 3% underestimated and 4% overestimated, and for invasive 41% and 50% overestimate on MRI and CESM respectively. LOAs for PathTotal varied from 60% under to a 2.4 or almost threefold over estimation. MRI was concordant with PathTotal in 36 (64%) cases compared with 32 (57%) for CESM. Both modalities concordant in 26 (46%) cases respectively.

CONCLUSION: Neither CEM nor MRI have sufficient accuracy to direct changes in planned treatment without needle biopsy confirmation.

ADVANCES IN KNOWLEDGE: Despite small mean differences in lesion size estimates using CEM or MRI, the 95% limits of agreement do not meet clinically acceptable levels.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Taylor, Burrows, Dessauvagie, et al. Accuracy and precision of contrast enhanced mammography versus MRI for predicting breast cancer size: how "good" are they really? Br J Radiol. 2023. PMID: 36753450. doi:10.1259/bjr.20211172

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。